- MAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent
- MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA’s Approval of a Telomerase Inhibitor Agent Therapy
- MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent
- MAIA Biotechnology Reveals New Clinical Data Showing THIO’s Strong Efficacy in Non-Small Cell Lung Cancer
- MAIA Biotechnology to Present at the BIO International Convention 2024
- MAIA Biotechnology Abstract Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
- MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement
- MAIA Biotechnology Announces Share Purchase by Director Stan Smith, Ph.D. in Private Placement
More ▼
Key statistics
On Tuesday, Maia Biotechnology Inc (MAIA:ASQ) closed at 3.70, -38.23% below its 52-week high of 5.99, set on Jun 03, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.92 |
---|---|
High | 4.24 |
Low | 3.30 |
Bid | 3.48 |
Offer | 3.66 |
Previous close | 3.75 |
Average volume | 218.10k |
---|---|
Shares outstanding | 21.84m |
Free float | 17.94m |
P/E (TTM) | -- |
Market cap | 81.89m USD |
EPS (TTM) | -1.57 USD |
Data delayed at least 15 minutes, as of Jul 23 2024 21:10 BST.
More ▼